SAN DIEGO - June 27, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
On June 12 th, I issued a detailed note referencing a landmark
discovery that cancer-secreted exosomes seed the spread of metastasis in
melanoma patients, and added that the Aethlon Hemopurifier®, which we
have been advancing with promising results in the treatment of hepatitis
c (HCV) infected individuals, has been validated in vitro to capture a variety of cancer-secreted exosomes, including those tested from melanoma patients.
Last week, we disclosed that the U.S. Patent and Trademark Office (USPTO) provided a Notice of Allowance for U.S. Patent Application
No. 12/282152 entitled "Extracorporeal Removal of Microvesicular
Particles," which provides us with broad rights to remove immune
suppressive microvesicular particles, which include but are not limited
to exosomes, from the circulation of treated patients.
Today, I am pleased to disclose that a paper authored by members of
our Aethlon team, entitled, "Exosome Removal as a Therapeutic Adjuvant
in Cancer" was published this morning in the Journal of Translational
Medicine and is now accessible online at www.translational-medicine.com.
We believe the publication to be quite timely as cancer-secreted
exosomes have recently emerged to become a vital therapeutic target as
they play an instrumental role in promoting tumor progression by
inducing programmed cell death of anti-cancer immune cells. As a result
of inhibiting the immune response, exosomes increase the proliferation
and spread of many forms of cancer. The particles also seed the spread
of tumor metastasis, promote angiogenesis (essential for tumor survival
and growth), increase tumor aggressiveness, and contribute to
anti-cancer drug resistance.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices
that address unmet medical needs in cancer, infectious disease, and
other life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of therapeutics that target the selective removal of disease
enabling particles from the entire circulatory system. The Aethlon
ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address
infectious disease and cancer; HER2osome™ to target HER2+ breast cancer,
and a medical device being developed under a contract with the Defense Advanced Research
Projects Agency (DARPA) that would reduce the incidence of sepsis in
combat-injured soldiers and civilians. For more information, please
visit www.aethlonmedical.com.
All financial
disclosures, anticipated revenue recognition amounts and other
information related to the financial results and operations of the
Company set forth above are unaudited and are subject to year-end audit
adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Aethlon Medical, Inc. to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties
include, without limitation, the ability for the Company to derive
business partnerships or future revenue streams using the Aethlon ADAPT™
system including the ability to introduce a targeted breast cancer
therapy known as HER2osome™, there is no assurance that FDA will approve
the initiation of the company's clinical programs or provide market
clearance of the company's products, the ability to achieve the goals
set out in the DARPA contract, future human studies of the Aethlon
Hemopurifier® as an adjunct therapy to improve patient responsiveness to
established cancer therapies, the company's ability to raise capital
when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products
either internally or through outside companies and provide its services,
the impact of government regulations, patent protection on the
Company's proprietary technology,
product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a
variety of factors, including the risks associated with the effect of
changing economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer:
AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to
publish news and distribute content through Investordeas.com Newswire
and its syndicated partners and blogs
No comments:
Post a Comment